prevalence of disorders such as dyspepsia or the ... · fernándezmartínez,rafael ferrón gómez,...

2
Peña, C; Aliaga, A; Amaro, L; Recio C; Martín, L; Megia, C; Varas, R. Background Objectives Methods Results Conclusions To determine the degree of adherence and knowledge of patients using PPIs and to study the impact of the community pharmacist intervention on the patient’s quality of life. The intervention of community pharm- acist, through the Dispensing Service, significantly increases the knowledge and adherence to PPIs. The significant increase in the number of patients without pain/discomfort (according to EuroQoL Questionnaire) at the end of the study, indicates that the improvement in knowledge and adherence to PPIs may be associated with an improvement in the quality of life. Observational, descriptive, multicentre study. The recruitment of patients was made between April-June 2013.The selection criteria were patients 18 years old and asking for the dispensing of a PPI prescription. Each patient attended 3 visits: V1 (t=0), V2 (t=1. 5 months) and V3 (t=3 months). Adherence to treatment was assessed with the Morisky-Green Test, the knowledge level using the CPM Questionnaire and quality of life by using EuroQoL 5D 3P. Prevalence of disorders such as dyspepsia or the gastroesophageal reflux disease is very high in Spain. It is estimated that the 39% of population has suffered dyspepsia symptoms sometime. The lack of adherence to treatment may have an important role in the failure of treatment with Proton Pump Inhibitors (PPIs). The community pharmacist, by knowledge, skills and location, is very well positioned to identify adherence and knowledge problems of PPIs. 1. The study had the participation of 146 pharmacists-investigators. The full list of investigators will be available during the Congress. 2. Available at Aten Primaria. 2009;41(12):661–9 General Pharmaceutical Council of Spain - Villanueva, 11 - 7º - 28001 MADRID - Spain - Telf: 91 431 25 60 - Fax: 91 432 81 00 - E Mail: [email protected] 1 Participation of 146 community pharmacists from all over Spain. 684 patients enrolled in the study – 610 final sample. The main causes for not completing the study were the lost to follow-up and the completion of the PPI treatment. 57.7% women and 42.3% men with an average age of 62.5 years. 49.8% of patients were 65 years old. Approximately the 50% of patients were polymedicated and had three or more diseases. Most commonly prescribed PPIs were omeprazole (56.8%) and pantoprazole (17.2%). 87.2% of cases were treatment continuations. Optimum knowledge about the PPI treatment went from 44.7% (V1) to 74.6% (V3) [p < 0,001]. Adherence to PPIs went from 48.4% (V1) to 78.5% (V3) [p < 0,001]. Quality of Life experienced an improvement of 4.65 points (p < 0,001), mainly due as a significant reduction in the number of patients without pain/discomfort at the end of the study compared to the V1. Omeprazole Pantoprazole Esomeprazole Lansoprazole Rabeprazole 56,8% 17,2% 10,8% 9,2% 9,2% PPI Use 2

Upload: others

Post on 19-Mar-2020

5 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Prevalence of disorders such as dyspepsia or the ... · FernándezMartínez,Rafael Ferrón Gómez, Marta Figueroa Hermo, Lucía Forcadell Berenguer, Yolanda Fuentes de Frutos, José

Peña, C; Aliaga, A; Amaro, L; Recio C; Martín, L; Megia, C; Varas, R.

Background

Objectives

Methods

Results

Conclusions

To determine the degree of adherence and knowledge of patients using PPIs and to study the

impact of the community pharmacist intervention on the patient’s quality of life.

The intervention of community pharm-acist, through the Dispensing Service, significantly increases the knowledge and adherence to PPIs.

The significant increase in the number of patients without pain/discomfort (according to EuroQoL Questionnaire) at the end of the study, indicates that the improvement in knowledge and adherence to PPIs may be associated with an improvement in the quality of life.

Observational, descriptive, multicentre study. The recruitment of patients was made between

April-June 2013.The selection criteria were patients ≥ 18 years old and asking for the dispensing

of a PPI prescription. Each patient attended 3 visits: V1 (t=0), V2 (t=1. 5 months) and V3

(t=3 months). Adherence to treatment was assessed with the Morisky-Green Test, the

knowledge level using the CPM Questionnaire and quality of life by using EuroQoL 5D 3P.

Prevalence of disorders such as dyspepsia or the gastroesophageal reflux

disease is very high in Spain. It is estimated that the 39% of population has

suffered dyspepsia symptoms sometime. The lack of adherence to treatment

may have an important role in the failure of treatment with Proton Pump Inhibitors (PPIs).

The community pharmacist, by knowledge, skills and location, is very well positioned to identify

adherence and knowledge problems of PPIs.

1. The study had the participation of 146 pharmacists-investigators. The full list of investigators will be available during the Congress.

2. Available at Aten Primaria. 2009;41(12):661–9

General Pharmaceutical Council of Spain - Villanueva, 11 - 7º - 28001 MADRID - Spain - Telf: 91 431 25 60 - Fax: 91 432 81 00 - E Mail: [email protected]

1

Participation of 146 community pharmacists from all over Spain.

684 patients enrolled in the study – 610 final sample. The main causes for not completing the

study were the lost to follow-up and the completion of the PPI treatment.

57.7% women and 42.3% men with an average age of 62.5 years.

49.8% of patients were ≥ 65 years old.

Approximately the 50% of patients were

polymedicated and had three or more diseases.

Most commonly prescribed PPIs were omeprazole

(56.8%) and pantoprazole (17.2%). 87.2% of cases

were treatment continuations.

Optimum knowledge about the PPI treatment

went from 44.7% (V1) to 74.6% (V3) [p < 0,001].

Adherence to PPIs went from 48.4% (V1) to

78.5% (V3) [p < 0,001].

Quality of Life experienced an improvement of 4.65 points (p < 0,001), mainly due as a significant

reduction in the number of patients without pain/discomfort at the end of the study compared

to the V1.

Omeprazole Pantoprazole Esomeprazole

Lansoprazole Rabeprazole

56,8%

17,2% 10,8%

9,2%

9,2%

PPI Use

2

Page 2: Prevalence of disorders such as dyspepsia or the ... · FernándezMartínez,Rafael Ferrón Gómez, Marta Figueroa Hermo, Lucía Forcadell Berenguer, Yolanda Fuentes de Frutos, José

PHARMACISTS-INVESTIGATORS Study Coordinators (General Pharmaceutical Council of Spain): Carmen Peña; Ana Aliaga; Luis Amaro; Laura Martín; Carmen Megía; Raquel Varas Pharmacists-investigators: Acosta Fernández, Benedicto Agustín Álvarez, Eduardo Almarza Camacho, Enrique Almorín Andrés, María Alonso Deive, Francisco Alonso Núñez, Mª Luisa Álvarez Castro, Beatriz Álvarez Pedrero, José Ignacio Araujo Rodríguez, Antonio Aristi Alberdi, Ohiana Ávila Torvisco, Raquel Barco Martín, Inés Barreiro Vidal, Mª Carmen Barrosa Vázquez, Manuela Beltrán Ramírez, Constanza Boullosa Curra, Dolores Brita Casillas, Dara Cáceres Ferrer, Juan Pedro Calatayud Gómez, Eva Cardero Blanco, Mª Cruz Carretero González, Mª África Castillo Fernández, Ana Reyes Castro Ávila, Rita Cerdeiras Uría, Mª José Cobo García, Marina Codorniu Martínez, Rosa Collado Díaz, Carmen Patricia Coronilla Pérez, Ruth Cortes Selva, Josefa De Mingo García, Eva Mª De Pedro Blázquez, Susana De Pedro Pordomingo, Emilio Del Cañizo Tejerizo, Sonsoles Díaz Redondo, Javier Pedro Diéguez Marín, Marina Díez Martín, Jesús Doncel Santamaría, Mª Luisa Escartín Gil, Cristina Esplugues Canto, Susana Esteban López, Ana Feijoo Covelo, Melca Fernández Alonso, Mª Dolores Fernández Martínez, Rafael Ferrón Gómez, Marta Figueroa Hermo, Lucía Forcadell Berenguer, Yolanda Fuentes de Frutos, José Enrique Fuentes Marchal, Antonio Jesús Galiana de la Villa, Eva Marta García Carrillo, Julia García García, Mª Carmen García Moratalla, Ana Mª García Ruiz, Eva Mª García Vázquez, Victoria Gil Guerrero, María González Álvarez, Janet González Aparisi, Carmen González García, Celia Mª González Martínez, Mª Magdalena González Pérez, Mª Pilar Grimeldos Ruiz, Mª Dolores Guerrero Luque, Encarnación Guirao Sánchez, Eva Hernández Hernández, Mª Luisa Huarte, Joaquina Iglesias Maceiras, Almudena Irurtia Oricain, Teresa Jara Roura, Pilar Lázaro Navarro, Marta López Liebanas, Raquel López Manzanedo, Lourdes Lucía Lorenzo Sánchez, Gemma Luque del Moral, Raúl Maestre González-Nicolás, Cecilia Marijuan Masa, Rosario Martin Cancho, Mª Fernanda Martínez Fernández, Fátima Martínez Muñoz, Aurora Martínez Pérez, Mariana Dolores

Mayela Hervas Hernando, Laura Mena Escobar, Rosario

Mera Gallego, Rocío Monente, Ana Monllau Mayor, Lina Monsonis Peirats, Reyes Montalbán Soler, Luis Montijano Cabrera, Natalia Morillo Lisa, Rosa Mª Mutiozabal Pascual, Ignacio Navarro Madrid, Miguel Ángel Nogueras Mayoral, Joaquín Olleros Sánchez Ruiz, Paloma Ortega Muñoz, Fermina Otero Suarez, Dolores Oya Amate, Mª Jesús Pascual Lavilla, Antonio Jesús Peláez Alonso, Mª Teresa Pérez Muñoz, José Andrés Piñeiro Fuentes, Carlos M. Plasencia Cano, Manuela Porras González, Ana Virginia Prieto Pacho, Mª Teresa Pruja Mach, Dolors Ramírez Rodríguez, Isabel Raya Díaz, Trinidad Mª Recuenco Morillas, Mª Victoria Reyner Torres, Anna Ribera Pérez, Encarnación Risquez Madridejos, Juan Pedro Robina Hidalgo, Carmen Rodrigo Rodríguez, Blanca Mª Rodrigo Rodríguez, Pilar Rodríguez León, Mª de la Cinta Rodríguez Peláez Peña, Ana Mª Rodríguez Santiago, Cristina Román Tamayo, Luis Evelio Rovaris Castellano, Javier Rubio Horcajada, Esther Saborit Sola, Albert Sainz Fernández, Mª Jesús Sal del Rio Arganza, Elvira San Cecilio Pérez, Celia Sánchez Arrobas, Julia Sánchez Carrasco, Beatriz Sánchez Fernández, Elena Sánchez Flores, Eva Belén Sánchez Losa, Emilio Sánchez Riaño, Virginia Sanchidrian Sánchez, Olga Santamaría Pablos, Ana Serrano Conejero, Antonio Serrano Téllez, Paula Sueiro Justel, Julia Tejada Vicuña, Natalia Tendero Baima, Marta Torres Guerrero, Almoraima Varela Martínez, Carmen Vicente Remón, Ana Viedma Bernal, Cristina Vieitez Martín, Beatriz Villanueva Pla, Francisco Villanueva Romero, Amelia Lucía

Villasan García, Mª Victoria Zamarbide, Cristina

Pharmacy Chambers:

Alicante Cáceres Girona Jaen Ourense Valladolid Ávila Cantabria Granada Las Palmas Salamanca Zamora Asturias Ciudad Real Guadalajara León Soria Zaragoza Barcelona Cuenca Huelva Madrid Teruel Burgos Gipuzkoa Huesca Murcia Valencia